Probiotic Visbiome for Inflammation and Translocation in HIV II (PROOV IT II)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Modern antiretroviral therapy (ART) has transformed the clinical care and lived experience of HIV infection. However, increased rates of adverse health conditions that are related to immune activation, such as cardiovascular disease (CVD) and neurodegenerative disease in ART-treated individuals persist. An important cause of this inflammation is the gut CD4 T cell loss and the "leaking" or translocation of luminal gut bacteria and other microbes across the bowel wall and into the bloodstream.
The use of complementary and alternative therapies is very common among people living with HIV, with estimates ranging from 16-60%. However, their efficacy has generally not been well demonstrated. Probiotics are live microbes that may provide a health benefit to the host and the investigators believe that the simultaneous use of probiotics along with ART will improve gut CD4 T cell restoration and function and therefore reduce microbial translocation and immune activation.
A major challenge to HIV treatment is the suboptimal CD4 T cell count despite successful HIV suppression on ART in immunologic non-responders (INRs). These individuals are at increased risk of AIDS-related deaths and non-AIDS related comorbidities that may be associated with increased immune activation and microbial translocation from the gut mucosa. With limited treatment options, alternative therapies to reduce inflammation and restore gut immunology will be important. Probiotic Visbiome consists of a high potency blend of eight different probiotics. The precise mechanism of action of Visbiome is unknown,but preclinical studies have shown that Visbiome may modulate the immune response towards an immunoregualtory phenotype with increased the levels of IL-10 and reduced levels of proinflammatory cytokines (TNFα, IL1β and IL-8). Therefore,the investigators believe that the "beneficial" bacteria from Visbiome will accelerate the normalization of gut immune cells and function in HIV-infected INRs. It is hypothesized consumption of Visbiome for 48 weeks will help restore the immune system in INRs who have suboptimal immune reconstitution to currently available ART. Resolution of gut immune cells will mean that microbial translocation and immune activation will be normalized and will reduce the rates of HIV-associated comorbidities.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Documented HIV-1 infection
- Male adult (age >18 years)
- Currently on ART (>2 years but <10 years)
- Undetectable HIV-1 viral load <50 copies/ml for the past 2 years (1 viral blip below 500 copies/ml permitted in the past year)
- Last CD4 count <350 cells/μl, and >70% over the past 2 years <350 cells/μl
- Ability to provide informed consent
Exclusion criteria
-
Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance
-
Taking pharmaceutical-grade probiotics
-
Any of the following abnormal laboratory results in screening:
- Hemoglobin <85 g/L
- Neutrophil count <750 cells/μl
- Platelet count <50,000 cells/μL
- AST or ALT >5X the upper limit of normal
-
Colitis
-
Liver fibrosis (decompensated cirrhosis), portal hypertension or clinical hepatitis
-
Other significant underlying disease (non-HIV-1) that might impinge upon disease progression or death
Trial design
Primary purpose
Allocation
Interventional model
Masking
36 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
Rupert Kaul, MD; Rodney Rousseau
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal